JPSIM Journal of Pakistan Society of Internal Medicine J Pak Soc Intern Med 2709-8729 2710-0804 Pakistan Society of Internal Medicine 10.70302/jpsim.v6i2.2530 jpsim.v6i2.2530 Original Research Short-Term Outcomes in Membranous Nephropathy: Insights from A Single Study Center Khan Raheel x_raheel@yahoo.com * Malik Suhail Iqbal Idrees Muhammad Khalid Abbass Anam Riaz Muhammad Tahir Ali Qazi Masroor Bahawal Victoria Hospital, Bahawalpur *Correspondence: Raheel Khan (x_raheel@yahoo.com) 05 06 2025 2025 6 2 159 165 18 10 2024 22 01 2025 25 04 2025 Copyright © 2025 The Author(s) 2025 The Author(s) https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Objective

To determine the short-term outcomes of membranous nephropathy (MN) in patients visiting outpatient department of nephrology, Bahawal Victoria Hospital, Bahawalpur.

 Methodology

Patients of either gender and any age, having renal biopsy proven MN, visiting outpatient department of nephrology between October 2021 to August 2024, and treated for a minimum duration of 6 months were analyzed. All of the patients underwent a systematic physical examination, and detailed information about their medical history was gathered. Patients were then subjected to necessary baseline investigations. Follow up visits were planned every month and final outcome was labeled after 6 months treatment.

 Results

In a total of 178 patients with MN, the mean age was 32.25±12.86 years. There were 117 (65.7%) male patients. The mean duration of symptoms was 7.80±13.04 months. Most frequent types of treatment advised were conservative and cyclical regimens used in 80 (44.9%), and 33 (18.5%) patients, respectively. Post-treatment, 74 (41.6%) patients had complete proteinuria remission, 93 (52.2%) partial remission, whereas 11 (6.2%) patients had nephrotic proteinuria progression. Post-treatment proteinuria status was having significant association with duration of symptoms (p=0.003), baseline proteinuria (p

 Conclusion

This study emphasizes the importance of baseline parameters and treatment modalities in predicting and influencing post-treatment outcomes in MN, providing valuable insights for more targeted and effective patient care. Favorable short-term outcomes were reported in vast majority of patientswith membranous nephropathy.

 Keywords Membranous nephropathy Nephrotic proteinuria Proteinuria Serum albumin Serum creatinine. Ethics Statement

Ethics committee: Ethics Committee, Quaid-e-Azam Medical College, Bahawalpur, Pakistan. Approval number: 1226/DME/QAMC Bahawalpur, dated October 25, 2021.

 References Gu Y, Xu H, Tang D. Mechanisms of Primary Membranous Nephropathy. Biomol. 2021;11(4):513. Ronco P, Debiec H. Molecular Pathogenesis of Membranous Nephropathy. Annu Rev Pathol. 2020;15:287-313. Peleg Y, Bomback AS, Canetta PA, Radhakrishnan J, Appel GB, Ahn W. Late relapses of membranous nephropathy: A case series. Kidney360. 2021;2(6):974-982. 10.34067/KID.0007712020 Dantas M, Silva LBB, Pontes BTM, Dos Reis MA, de Lima PSN, Moysés Neto M. Membranous nephropathy. J Bras Nefrol. 2023;45(2):229-243. von Groote TC, Williams G, Au EH, Chen Y, Mathew AT, Hodson EM, et al. Immunosuppressive treatment for primary membranous nephropathy in adults with nephrotic syndrome. Cochrane Database Syst Rev. 2021;11(11):CD004293. Scolari F, Alberici F, Mescia F, Delbarba E, Trujillo H, Praga M, et al. Therapies for membranous nephropathy: A tale from the old and new millennia. Front Immunol. 2022;13:789713. Teisseyre M, Cremoni M, Boyer-Suavet S, Ruetsch C, Graca D, Esnault VLM, et al. Advances in the management of primary membranous nephropathy and rituximab-refractory membranous Nephropathy. Front Immunol. 2022;13:859419. Ponticelli C, Praga M, Moroni G. Calcineurin inhibitors in membranous nephropathy. Kidney Int Rep. 2021;6(10):2537-2539. 10.1016/j.ekir.2021.08.008 Hashmi AA, Hussain ZF, Edhi MM, Mumtaz S, Faridi N, Khan M. Insight to changing morphologic patterns of glomerulopathy in adult Pakistani patients: an institutional perspective. BMC Res Note. 2016;9(1):73. Kumar MKH, Sandhu J, Sandhu JS. Profile and primary treatment outcomes in membranous nephropathy. Saudi Med J. 2022;43 (9):1051-6 He P, Zha Y, Liu J, Wang H, He L. Clinical outcomes of patients with primary membranous nephropathy and subnephrotic proteinuria. Front Med. 2021;8:737700. Jha V, Ganguli A, Saha TK, Kohli HS, Sud K, Gupta KL, et al. A randomized, controlled trial of steroids and cyclophosphamide in adults with nephrotic syndrome caused by idiopathic membranous nephropathy. J Am Soc Nephrol. 2007;18(6):1899-1904. Ram R, Guditi S, Kaligotla Venkata D. A 10-year follow-up of idiopathic membranous nephropathy patients on steroids and cyclophosphamide: a case series. Ren Fail. 2015;37(3):452-5. Ramachandran R, Yadav AK, Kumar V, Pinnamaneni VST, Nada R, Ghosh R, et al. Two-year follow-up study of membranous nephropathy treated with tacrolimus and corticosteroids versus cyclical corticosteroids and cyclophosphamide. Kidney Int Rep. 2017;2(4):610-6. Eriguchi M, Oka H, Mizobuchi T, Kamimura T, Sugawara K, Harada A. Long-term outcomes of idiopathic membranous nephropathy in Japanese patients treated with low-dose cyclophosphamide and prednisolone. Nephrol Dial Transplant. 2009;24(10):3082-38. . Qin HZ, Liu L, Liang SS, Shi JS, Zheng CX, Hou Q, et al. Evaluating tacrolimus treatment in idiopathic membranous nephropathy in a cohort of 408 patients. BMC Nephrol 2017;18(1):2. Westermann L, Rottmann FA, Hug MJ, Staudacher DL, Wobser R, Arnold F, et al. Clinical covariates influencing clinical outcomes in primary membranous nephropathy. BMC Nephrol. 2023;24(1):235. Wang YN, Feng HY, Nie X, Zhang Y, Zou L, Li X, et al. Recent advances in clinical diagnosis and pharmacotherapy options of membranous nephropathy. Front Pharmacol. 2022;13:907108.